The UK and US have finalized a major trade agreement that will keep zero import taxes on UK drug products being sold in the American market.
Agreement Details of the Pact
As part of the deal, the UK has agreed to increase expenditure on drugs through the NHS. This pledge ensures that import taxes on these key goods will stay at nothing for a period of 36 months.
This agreement is in response to recent threats to dramatically increase duties on branded drug imports, with potential rates discussed as high as 100%.
"This deal between the Britain reinforces the international landscape for innovative medicines and establishes long-overdue balance to U.S.–U.K. medicine commerce," an announcement declared.
Trade Importance
Drugs represent one of the the United Kingdom's biggest goods shipped to the United States, which is easily the largest destination for large British pharmaceutical firms.
Statistics indicate that in the year prior to the third quarter, the UK sold drugs worth over eleven billion pounds to the US. This figure made up nearly one-fifth of total UK exports in that span.
"This agreement protects employment, stimulates funding and facilitates the UK to emerge as a international leader for biotech and pharma," a government official stated.
Key British Pledges
The agreement entails several key changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to raise overall public funding on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to prevent overspending will be capped at fifteen percent. Previously, rebates topped twenty percent.
Broader Context
The pact comes amid a long-running dispute between the sector and the British authorities over spending levels and NHS adoption.
The disagreement were exacerbated by claims that US patients were paying several times more for the equivalent treatments than people in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar funding commitments have been pledged toward American operations.
One official stated that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had decreased as a proportion of its resources over the past decade.
